CN107105744A - 用于人营养品的25‑羟基维生素d与抗氧化剂/抗炎剂的组合 - Google Patents
用于人营养品的25‑羟基维生素d与抗氧化剂/抗炎剂的组合 Download PDFInfo
- Publication number
- CN107105744A CN107105744A CN201680005758.1A CN201680005758A CN107105744A CN 107105744 A CN107105744 A CN 107105744A CN 201680005758 A CN201680005758 A CN 201680005758A CN 107105744 A CN107105744 A CN 107105744A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- heart
- nutriment
- antiinflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003963 antioxidant agent Substances 0.000 title abstract description 92
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 88
- 230000003078 antioxidant effect Effects 0.000 title abstract description 50
- 239000011782 vitamin Substances 0.000 title description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 85
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 38
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 38
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 38
- 229940046009 vitamin E Drugs 0.000 claims abstract description 38
- 239000011709 vitamin E Substances 0.000 claims abstract description 38
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 31
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 31
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 31
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 26
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims abstract description 24
- 235000021318 Calcifediol Nutrition 0.000 claims abstract description 7
- 206010036049 Polycystic ovaries Diseases 0.000 claims abstract description 3
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims description 39
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 claims description 34
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 30
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 210000001519 tissue Anatomy 0.000 claims description 24
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 22
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 22
- 230000000975 bioactive effect Effects 0.000 claims description 22
- 229940106189 ceramide Drugs 0.000 claims description 22
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 22
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 21
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 20
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 claims description 17
- 235000012682 canthaxanthin Nutrition 0.000 claims description 17
- 239000001659 canthaxanthin Substances 0.000 claims description 17
- 229940008033 canthaxanthin Drugs 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 16
- 229930003316 Vitamin D Natural products 0.000 claims description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 16
- 235000013793 astaxanthin Nutrition 0.000 claims description 16
- 239000001168 astaxanthin Substances 0.000 claims description 16
- 229940022405 astaxanthin Drugs 0.000 claims description 16
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 16
- 230000006872 improvement Effects 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- 239000011669 selenium Substances 0.000 claims description 16
- 235000019166 vitamin D Nutrition 0.000 claims description 16
- 239000011710 vitamin D Substances 0.000 claims description 16
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 16
- 229940046008 vitamin d Drugs 0.000 claims description 16
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 15
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 15
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 15
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 15
- 235000012680 lutein Nutrition 0.000 claims description 15
- 239000001656 lutein Substances 0.000 claims description 15
- 229960005375 lutein Drugs 0.000 claims description 15
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 15
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 15
- 235000010930 zeaxanthin Nutrition 0.000 claims description 15
- 239000001775 zeaxanthin Substances 0.000 claims description 15
- 229940043269 zeaxanthin Drugs 0.000 claims description 15
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 14
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 229960002685 biotin Drugs 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 229910052711 selenium Inorganic materials 0.000 claims description 14
- 235000011649 selenium Nutrition 0.000 claims description 14
- 206010022489 Insulin Resistance Diseases 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 13
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 13
- 150000003626 triacylglycerols Chemical class 0.000 claims description 13
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 12
- 235000013734 beta-carotene Nutrition 0.000 claims description 12
- 239000011648 beta-carotene Substances 0.000 claims description 12
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 12
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 claims description 12
- 229960002747 betacarotene Drugs 0.000 claims description 12
- 239000010949 copper Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 12
- 239000011701 zinc Substances 0.000 claims description 12
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 10
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 10
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 10
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- 229930003471 Vitamin B2 Natural products 0.000 claims description 10
- 229940108928 copper Drugs 0.000 claims description 10
- 229910052802 copper Inorganic materials 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 235000012661 lycopene Nutrition 0.000 claims description 10
- 239000001751 lycopene Substances 0.000 claims description 10
- 229960004999 lycopene Drugs 0.000 claims description 10
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims description 10
- 229960003512 nicotinic acid Drugs 0.000 claims description 10
- 239000011664 nicotinic acid Substances 0.000 claims description 10
- 230000000770 proinflammatory effect Effects 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 10
- 235000019164 vitamin B2 Nutrition 0.000 claims description 10
- 239000011716 vitamin B2 Substances 0.000 claims description 10
- 235000016804 zinc Nutrition 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- 238000009825 accumulation Methods 0.000 claims description 9
- 230000009885 systemic effect Effects 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 7
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 7
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims description 7
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims description 7
- 206010003445 Ascites Diseases 0.000 claims description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 7
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 206010003119 arrhythmia Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 210000002414 leg Anatomy 0.000 claims description 7
- 229940055726 pantothenic acid Drugs 0.000 claims description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims description 7
- 239000011713 pantothenic acid Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000008595 infiltration Effects 0.000 claims description 6
- 238000001764 infiltration Methods 0.000 claims description 6
- 230000001788 irregular Effects 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 230000005961 cardioprotection Effects 0.000 claims description 5
- 230000010036 cardiovascular benefit Effects 0.000 claims description 5
- 210000002064 heart cell Anatomy 0.000 claims description 5
- 238000005728 strengthening Methods 0.000 claims description 5
- 108091006106 transcriptional activators Proteins 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 230000005800 cardiovascular problem Effects 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 210000002976 pectoralis muscle Anatomy 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 2
- 241000227653 Lycopersicon Species 0.000 claims 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- -1 β-carrot Element Chemical compound 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 abstract description 90
- 235000015872 dietary supplement Nutrition 0.000 abstract description 30
- 235000005911 diet Nutrition 0.000 description 46
- 230000037213 diet Effects 0.000 description 46
- 239000013589 supplement Substances 0.000 description 32
- 241000287828 Gallus gallus Species 0.000 description 28
- 235000013372 meat Nutrition 0.000 description 25
- 239000003925 fat Substances 0.000 description 23
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 235000019197 fats Nutrition 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 18
- 210000001672 ovary Anatomy 0.000 description 14
- 208000008589 Obesity Diseases 0.000 description 13
- 235000021050 feed intake Nutrition 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 12
- 244000144977 poultry Species 0.000 description 12
- 229940088594 vitamin Drugs 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 238000011161 development Methods 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 8
- 206010042434 Sudden death Diseases 0.000 description 8
- 238000009395 breeding Methods 0.000 description 8
- 230000001488 breeding effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 210000002969 egg yolk Anatomy 0.000 description 6
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 6
- 210000004681 ovum Anatomy 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000017448 oviposition Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000006029 Cardiomegaly Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000010746 mayonnaise Nutrition 0.000 description 4
- 239000008268 mayonnaise Substances 0.000 description 4
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000008935 nutritious Nutrition 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 208000015124 ovarian disease Diseases 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 235000010960 Atriplex hastata Nutrition 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 240000006122 Chenopodium album Species 0.000 description 2
- 235000009344 Chenopodium album Nutrition 0.000 description 2
- 235000008645 Chenopodium bonus henricus Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 239000011774 beta-cryptoxanthin Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000031592 cardiac muscle cell apoptotic process Effects 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000021236 calorie-restricted diet Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000002268 gamma-terpinene derivatives Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/065—Diphenyl-substituted acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及25‑羟基维生素D3(“25‑OH D3”)与抗氧化剂/抗炎剂(抗坏血酸、维生素E和至少一种类胡萝卜素)的组合用于制备药品、营养品或食品补充剂的用途,所述药品、营养品或食品补充剂能够改良在与多囊卵巢5综合症和心血管疾病相关的人中观察到的多种问题。还提供了含有25‑OH D3和抗氧化剂/抗炎剂的药品、营养品和食品补充剂以及预混物。
Description
发明简介
本发明涉及用于人营养品、药品和食品补充剂中的25-羟基维生素D(“25-OH D3”和/或“25-OH D2”)与抗氧化剂/抗炎剂(抗坏血酸、维生素E和类胡萝卜素)的组合。这种营养补充剂组合防止与食欲过剩(hyperphagia)和相关肥胖有关的多种不良反应。本发明还涉及含有25-羟基维生素D与抗氧化剂/抗炎剂的组合的营养品、营养预混物、药品和食品。
发明背景
本申请要求2015年1月15日提交的美国临时申请62/103769和2015年5月8日提交的EP15166937.1的优先权,两者均通过引用并入本文。
食欲过剩(暴饮暴食)及其相关肥胖可引起人的多种问题。这些问题包括:卵巢功能障碍和不育症以及与心血管系统和血糖系统相关的代谢疾病。
有趣的是,女性卵巢疾病的一种动物模型是家禽。家养产蛋母鸡是卵巢癌高发的唯一非人动物。参见Johnson等人2013Nature 13:432-436和Walzem等人2014Advances inNutrition 5:199-206。母鸡卵巢癌的进展以及腹水和转移性生长的位置与在女性中观察到的相似。
一些家禽品种经历与食欲过剩相关的肥胖症。一般来说,农民会限制提供给禽群(flock)的食物量,以防止肥胖的不良后果。然而,通常难以确定将确保期望的禽群生长的要提供的饲料的恰当量,并且在受限制的饲喂条件下,个体可变得有攻击性,不仅会伤害其它禽类,而且自己也会变肥胖。
在生殖发育期间,过量饲喂的雌性肉种鸡不仅产生过大的黄卵泡,而且还产生较多闭锁的黄滤泡,并且通常展示出异常产卵和缺陷卵综合症(EODES),EODES包括几种生殖问题,例如卵泡闭锁,产生软壳蛋或膜性蛋,双黄卵,卵黄腹膜炎(腹腔中存在卵黄),多卵日(multiple egg days)和产卵不按顺序发生,导致不可成形(unsettable)的蛋的产量增加。
对照性研究报告称:任意(voluntary)饲喂(即饲喂至饱食的肉种母鸡)导致卵产量不高,死亡率高和卵巢结构异常(主要是明显的分层卵泡闭锁)。与限量饲喂的母鸡相比,任意饲喂还引起代谢失调,其包括肥胖症增强;肝脏三酰甘油积累;血浆葡萄糖、非酯化脂肪酸、极低密度脂蛋白、三酰甘油、磷脂、神经酰胺和鞘磷脂的浓度升高。
此外,肝脏的和循环的神经酰胺和鞘磷脂积累,以及肝脏和脂肪组织中促炎性IL-1β表达的上调系统性显现为饱食饲料的母鸡中脂毒性的发展。神经酰胺是将某些营养物质(即饱和脂肪)和炎性细胞因子(例如肿瘤坏死因子-α,TNFα)连接到调节细胞功能以及拮抗胰岛素信号转导和线粒体功能的关键中间体。此外,由于其对特别敏感细胞类型的毒性作用,神经酰胺具有损害心脏、胰腺和脉管系统的能力。通过神经酰胺积累以及IL-1β、丝氨酸棕榈酰转移酶和鞘磷脂酶转录物丰度的上调以及分层卵泡内蛋白激酶Akt激活受到抑制进一步例证了脂毒性导致饱食饲料的母鸡中受损的卵巢功能障碍,包括卵泡闭锁、卵巢退化和循环雌二醇水平的降低。因此,体内证据描述了神经酰胺和IL-1β在介导肉种母鸡中过量饲喂诱导的卵泡闭锁和卵巢退化进展的作用。
尽管在商业肉种禽群中严格执行限量饲喂方案,但由于其内在的食欲过剩,仍然很容易过量饲喂种母鸡。此外,种鸡场管理者还面对着:在卵生产开始之前和期间以及在峰值生产之前、期间和之后,何时以及如何进行饲喂。要问的最根本问题是:种鸡场管理者可以应用哪种管理和营养工具以及如何实施,以改良超重母鸡中与肥胖相关的繁殖率的不利、有害的影响。
(25-OH-D3的注册商标;可从瑞士的DSM Nutritional Products获得)已被用于促进家禽、猪的骨骼健康和人的维生素D缺乏症。
25-OH D3和角黄素的组合也已经用于家禽。WO2010/057811(DSM IP ASSETS,BV)描述了这种组合用于改善家禽的孵化率、生育力和降低胚胎死亡率。该组合可以以商标MAXICHICK商购。所述专利公开中没有提到含有抗坏血酸和高维生素E水平,也没有提到改良食欲过剩相关肥胖症的不利影响的用途。
因为鸡在正常饲养条件下能够产生足够的维生素C,故维生素C(抗坏血酸)通常不作为补充剂包含在家禽饮食中。然而,在某些特定条件下,例如在热应激情况下,已使用了维生素C。
维生素E通常被添加到家禽饲料中。取决于动物的年龄,家禽种的推荐剂量往往在约50-100IU/kg饲料的范围内。
WO14/202433(DSM IP ASSETS B.V)教导了角黄素和25-OH D3的组合以改善内部卵品质,即增加包裹卵黄的卵黄膜的强度。没有教导向所述组合中添加抗坏血酸,也没有教导其在改良食欲过剩相关肥胖症的不利影响中的用途。
WO14/191153(DSM IP ASSETS B.V)教导了角黄素和维生素C、维生素E、硒中的至少一种以及任选的百里酚、丁子香酚、香草醛和γ-萜品烯中的至少一种的组合可以改善免疫状态、骨骼健康、骨骼发育以及生长和饲料转化,特别是当禽群经受与疫苗接种相关的应激时。
需要预防或延缓人卵巢疾病和心血管相关问题的发作,并调节与食欲过剩相关的体重增加。
发明详述
根据本发明,已发现:25-羟基维生素D(25-OH D3和/或25-OH D2)与抗氧化剂/抗炎剂的组合能够有益于卵巢健康,特别是多囊卵巢综合症。除了有益于卵巢健康之外,25-OH D与抗氧化剂/抗炎剂的组合还能够有益于心血管和代谢健康,并调节吃得过多的人的体重增加。根据本发明,还发现:传统上认为是抗氧化剂的生物活性物质还具有有益于卵巢和心血管健康的抗炎活性。
由于25-OH D2和25-OH D3能够在施用后以类似的方式起作用,所以想到25-OH D2或25-OH D3可以独立地与抗氧化剂/抗炎剂组合使用,或者25-OH D3和25-OH D2二者的混合物可以与抗氧化剂/抗炎剂组合使用。如果一起使用25-OH D2和25-OH D3,则25-OH D3:25-OH D2之比不是本发明的关键部分。单独使用的25-OH D3是优选的。
本发明的抗氧化剂/抗炎剂包含抗坏血酸、维生素E和类胡萝卜素的组合。类胡萝卜素是选自以下的至少一种:番茄红素、虾青素、隐黄质(cryptoxanthin)、β-胡萝卜素、叶黄素、玉米黄质(zeaxanthin)和角黄素。最优选的是番茄红素、虾青素、叶黄素和玉米黄质。因此、本发明的一个方面是25-OH D3、一种或多种上述类胡萝卜素、维生素E和抗坏血酸的组合。另一个实施方式是25-OHD2、一种或多种上述类胡萝卜素、维生素E和抗坏血酸的组合。另一个实施方式是25-OHD3、25-OHD2、一种或多种上述类胡萝卜素、维生素E和抗坏血酸的组合。
组合物
本发明的另一方面是25-OH D、一种或多种上述类胡萝卜素、维生素E和抗坏血酸的组合,其任选地还包含至少一种选自以下的其它生物活性成分:
维生素D、维生素B2、生物素、维生素B6、烟酸、锌、铜、锰和硒。优选地,25-OH D是25-OH D3。优选地,至少维生素D是其它生物活性成分。有时,其它生物活性成分至少包括维生素D和硒。在某些情况下,添加所有所述其它生物活性成分。
另一方面是25-OH D、一种或多种本发明的类胡萝卜素、维生素E和抗坏血酸的组合,其任选地还包含至少一种选自以下的其它生物活性成分:维生素D、维生素B2、维生素B6、烟酸、泛酸、叶酸、生物素、锌、铜、锰、硒及其组合。优选地,25-OH D是25-OH D3。有时,所述其它生物活性成分包括生物素。有时,所述其它生物活性成分包括维生素D和生物素。有时,所述其它生物活性成分包括所有上述任选的生物活性成分。
营养品、药品、饮食补充剂
本发明的另一方面是营养品(例如饮食补充剂)或药品,其包含25-OH D2或25-OHD3或它们的混合物、抗坏血酸、维生素E和一种或多种上述类胡萝卜素的组合。
另一个实施方式是营养品(例如饮食补充剂)或药品,其包含25-OH D、一种或多种上述类胡萝卜素、维生素E和抗坏血酸的组合,其任选地还包含至少一种选自以下的其它生物活性成分:维生素D、维生素B2、维生素B6、烟酸、锌、铜、锰、硒及其组合。优选地,25-OH D是25-OH D3。有时,所述其它生物活性成分至少包括维生素D和硒。在某些情况下,添加所有所述其它生物活性成分。
另一个实施方式是营养品(例如饮食补充剂)或药品,其包含25-OH D、一种或多种上述类胡萝卜素、维生素E和抗坏血酸的组合,其任选地还包含至少一种选自以下的其它生物活性成分:维生素D、维生素B2、维生素B6、烟酸、泛酸、叶酸、生物素、锌、铜、锰、硒及其组合。有时,所述其它生物活性成分包括生物素。优选地,25-OH D是25-OH D3。有时,所述其它生物活性成分包括维生素D和生物素。有时,其它生物活性成分包括所有上述任选的生物活性成分。
预混物
本发明的另一方面是用于营养品(例如食品补充剂或维生素补充剂)的预混物,其包含25-OH D、维生素E、抗坏血酸和一种或多种上述类胡萝卜素的组合。优选地,25-OH D是25-OH D3。预混物和随后的营养品改善/改良与卵巢相关的不利病症,特别是多囊卵巢综合症。在一些实施方式中,预混物或随后的营养品还包含至少一种选自以下的其它生物活性成分:
维生素D、维生素B2、维生素B6、烟酸、锌、铜、锰、硒及其组合。有时,所述其它生物活性成分至少包括维生素D和硒。在某些情况下,添加所有所述其它生物活性成分。
本发明的另一方面是用于营养品的预混物,其还包含至少一种选自以下的其它生物活性成分:维生素D、维生素B2、维生素B6、烟酸、泛酸、叶酸、生物素、锌、铜、锰、硒及其组合。有时,所述其它生物活性成分包括生物素。有时,所述其它生物活性成分包括维生素D和生物素。有时,所述其它生物活性成分包括所有上述任选的生物活性成分。
使用本发明的营养品或药品时,人可以正常进食或过度进食,并且影响卵巢、心血管系统和代谢系统且通常与进食非热卡限制饮食(non-calorie restricted diet)相关的不良作用会达到较低程度或根本不存在。
附图简介
图1显示了响应随意(ad libitum)饲料摄取与25-OH D3+抗氧化剂/抗炎剂的组合的肉种母鸡的葡萄糖清除率和胰岛素分泌。饲喂3周后,通过翅静脉向母鸡注射单剂量的葡萄糖(0.5g/kg BW)。在输注葡萄糖后的指定时间点,通过翅静脉插管采集血样,n=3。
图2显示了响应随意饲料摄取与25-OH D3和抗氧化剂/抗炎剂的组合的肉种母鸡的组织白细胞介素-1β含量和血浆IL-6水平。在10周的饲喂试验之后收集组织和血液样品。具有不同上标字母的平均值显著不同(P<0.05),n=3。
图3显示了响应随意饲料摄取与25-OH D3和抗氧化剂/抗炎剂包含物的组合的肉种母鸡的组织STAT-3激活。在10周的饲喂试验之后收集组织和血液样品。具有不同上标字母的平均值显著不同(P<0.05),n=3。
图4-6显示了在响应随意饲料摄取与25-OH D3和抗氧化剂/抗炎剂包含物的组合的肉种母鸡的尸体剖检期间拍摄的图片。在10周的饲喂试验之后剖检母鸡尸体。
图7显示了饮食补充25-OH D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的产卵的影响。
图8显示了饮食补充25-OH D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的存活率的影响。
图9显示了饮食补充25-OH D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的体重的影响。
图10是一系列照片,其显示了:在受限制或随意饲料摄取情况下,饮食补充25-OH-D3+抗氧化剂/抗炎剂的死母鸡的心脏的总体形态。
图11是一系列照片,其显示了:在受限制或随意饲料摄取情况下,饮食补充25-OH-D3+抗氧化剂/抗炎剂的死母鸡的心脏的总体形态。
图12是一系列心电图(EGC),其显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的EGC的影响。箭头指向谱中的不规则。
图13是一系列EGS,其显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的心律不齐的ECG谱的影响。
图14显示了照片和图表,其显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的心肌纤维化的影响。(在35周龄时)
图15是这样的图表,其显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的血浆IL-6和IL-1β浓度的影响。
图16是这样的照片,其显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的心肌细胞凋亡的影响。(在35周龄时)
在本说明书和权利要求书全文中使用时,适用以下定义:
“25-OH D”是指任何形式的25-羟基维生素D(即25-OH D2或25-OH D3或其混合物)。25-OH D3特指25-羟基维生素D3;25-OH D2特指25-羟基维生素D2。
“维生素D”是指维生素D2、维生素D3或其组合。单独使用的维生素D3是优选的。
“食欲过剩”是过量进食;人的卡路里摄入量大于其能量消耗。
“改良体重增加”是指:在随意进食且同时摄入本文所述的抗氧化剂/抗炎剂与25-OH D的组合时,体重增加量显著更低。与进食热量受控的饮食相比,可能有正的体重增加。
在说明书和权利要求书全文中,“抗坏血酸”和“维生素C”可互换使用。
“基础饮食”是指向家禽提供了足够的维生素和矿物质,使得家禽的维生素和矿物质充足的饲料。
“25-OH-D3+抗氧化剂/抗炎剂”是指,在提供足够的维生素和矿物质以使得人不遭受维生素或矿物质缺乏或不足的饮食之外,以说明书中所述的剂量范围施用的25-OH D3、维生素E、本发明的类胡萝卜素(见下一段)和抗坏血酸的组合。任选地,且优选地,向25-OHD3、维生素E、角黄素和抗坏血酸的组合中添加选自以下的额外生物活性成分:维生素D、维生素B2、维生素B6、烟酸、泛酸、叶酸、生物素、锌、铜、锰、硒及其组合。
“本发明的类胡萝卜素”是指番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素中的至少一种。最优选的是番茄红素、虾青素、叶黄素和玉米黄质中的至少一种。通常,叶黄素和玉米黄质一起施用。
1.卵巢问题
根据本发明,已发现:使用包含25-OH D3、维生素E、一种或多种本发明的类胡萝卜素和抗坏血酸的营养品、食品补充剂或药品组合物能够特定地促进卵巢健康。使用本发明的营养品、食品补充剂或药品能够减轻、减少、改良或消除与多囊卵巢综合症相关的这些病症中的每一种。
家禽(特别是产卵母鸡)是人卵巢健康的公认实验模型。参见,例如Johnson等人2013“The hen as a model of ovarian cancer”Nature.com/reviews/cancer 13:432-436和Walzem等人2014“Obesity-Induced Dysfunction in Female Reproduction:Lessons from Birds and Mammals”Adv.Nutr 5:199-206。因此,家禽研究中收集的数据适用于人。
1.多囊卵巢综合症症状:患多囊卵巢综合症的女性经常经历的症状例如以下之中的一种或多种:肥胖、胰岛素抵抗、高甘油三酯血症、神经酰胺和非酯化脂肪酸(NEFA)的循环浓度升高,以及全身性促炎物质(包括IL-1β)。已发现:25-OH D3、维生素C、维生素E和本发明的类胡萝卜素的组合能够改良这些症状。
因此,本发明的另一方面是25-OH D3、维生素C、维生素E与一种或多种选自番茄红素、虾青素、隐黄质、β-胡萝卜素和角黄素的类胡萝卜素的组合用于至少一种选自以下的用途:
预防人多囊卵巢综合症;
治疗人多囊卵巢综合症;
延缓多囊卵巢综合症的发作;和
改良多囊卵巢综合症的症状。
本发明的另一方面是治疗人多囊卵巢综合症、改良多囊卵巢综合症的症状或延缓有发生多囊卵巢综合症的风险的人的多囊卵巢综合症发作的方法,所述方法包括:
向患有多囊卵巢综合症或有发生多囊卵巢综合症风险的人施用有效量的组合,所述组合包含:
25-羟基维生素D3、维生素C、维生素E和一种或多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素。在一个优选的方法中,向前述人施用一种或多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质和叶黄素。
2.代谢问题
通过使用本发明的饲料/预混物能够减轻、减少或消除的与食欲过剩相关的代谢问题包括:
a)清除未酯化的脂肪酸
b)改良血浆血脂异常(甘油三酯、鞘磷脂和神经酰胺)
c)改良肝脏、腿部、胸肌和心脏中的甘油三酯和神经酰胺积累
d)抑制组织促炎性IL-1β产生和血浆IL-6浓度
e)通过上调心脏中STAT-3(信号转导物和转录激活物3)的磷酸化来保护心脏并增强心脏功能
f)抑制免疫细胞浸润到心脏中
g)降低腹水的发生率。
这些上述观察到的改善的病症导致死亡率降低,胰岛素信号转导得到改善,脂毒性发生和全身性炎症减轻,以及针对养料过载诱导的心脏发病机理的心脏保护机制被激活。
3.心血管问题
禽群中的禽鸟可能会经历“猝死”。“猝死”是指单个禽鸟死亡,而没有在之前显示迹象或疾病或创伤。禽鸟看起来健康,但在短时间的翅膀拍打和腿部运动后迅速死亡,在此期间,它们通常翻转到背部朝下。它们还可能被发现以侧面或胸部朝下死亡。没有特定的重大损伤。最近的研究表明:死亡的禽鸟在心肌细胞和心内膜下浦肯野细胞中有损伤,这可有助于诊断。
我们进一步研究了该现象,如实施例3中所详述,在随意饲喂和饲喂受限制饮食的禽群中,包括或不包括25-OH D3与抗氧化剂/抗炎剂的组合。我们的一些结果如下。
根据本发明,已发现:在随意饲喂的禽鸟中,已经饲喂了25-OH-D3+抗氧化剂/抗炎剂的猝死禽鸟具有较高的体重,但相对较低的肝脏、腹部脂肪和心脏重量。在猝死禽鸟中,随意饲喂引起心脏适应性肥大;且某些肥大生长可在病理上发展成心室扩张。因此,心脏需要更高的收缩力来维持泵送功能以满足将氧递送到外周组织的血液供应的需要。这种状态可导致心脏衰竭。
重要的是,我们发现:25-OH-D3+抗氧化剂/抗炎剂降低了心脏病性发展,从而降低了随意饲喂的禽鸟心脏衰竭的发生率。因此,本发明的另一方面是25-OH-D3+抗氧化剂/抗炎剂用于减少可导致心脏衰竭的心脏问题的量的用途。
在受限制和随意饲喂的禽鸟中,具有25-OH-D3+抗氧化剂/抗炎剂的禽鸟展示出较少适应性肥大生长,从而支持了大部分过量养料可被分配到肌肉的假说,因此,用于增强泵送功能的心脏肥大生长不能满足较高生长速率(肌肉)的氧气供应的需要,从而可引起心律不齐和心脏衰竭。
25-OH-D3+抗氧化剂/抗炎剂包含物被认为具有以下作用:
·降低在死亡禽鸟的尸体剖检中观察到的心脏发病(扩张、心包积液、破裂)的发生率。
·降低ECG谱不规则发生率的量
·减少随意饲喂肉母鸡的心律不齐
·改良心脏发病所引起的猝死
·改良随意饲喂母鸡的心肌纤维化
·改良随意饲喂母鸡的慢性全身性炎症
·改良受限制或随意饲料摄取的母鸡的心脏细胞凋亡。
因此,25OH D3+抗氧化剂能够保护心血管系统。
使用补充的25-OH D3和抗氧化剂/抗炎剂改良相关的有害作用具有多种心血管益处。因此,本发明包括25-OH D3和抗氧化剂/抗炎剂用于至少一种选自以下的心血管益处的用途:
a)清除未酯化的脂肪酸;
b)改良血浆血脂异常(甘油三酯、鞘磷脂和神经酰胺);
c)改良肝脏、腿部、肌肉和心脏中的甘油三酯和神经酰胺积累;
d)抑制组织促炎性IL-1β产生和血浆IL-6浓度;
e)通过上调心脏中STAT-3(信号转导物和转录激活物3)的磷酸化来保护心脏并增强心脏功能;
f)抑制免疫细胞浸润到心脏中;
g)降低腹水的发生率;
h)降低心血管问题造成的死亡的发生率;
i)降低心脏发病(扩张、心包积液、破裂)的发生率;
j)降低ECG谱不规则发生率的量;
k)减少心律不齐的发生;
l)改良心肌纤维化;
m)改良慢性全身性炎症;和
n)改良心脏细胞凋亡
o)改进胰岛素抵抗和/或血糖调节。
3.剂量
在本发明的一个方面,将本发明的25-OH D3与抗氧化剂/抗炎剂的组合施用至维生素充足的个体而非缺乏维生素的个体。维生素充足状态优选地归因于为人提供至少最少量的维生素和矿物质的均衡饮食。因此,优选在基础饮食之外还使用本发明的组合。
25-OH D3:25-OH D3以这样的日剂量存在,为1μg至50μg,优选约5μg和25μg之间。在一些实施方式中,使用10μg。
维生素E:日剂量中的量可以为5-750mg/天,优选为10-600mg/天,更优选为100-500mg/天。在一些实施方式中,使用400mg。
抗坏血酸:抗坏血酸的量可以为1-1000mg/天,优选为100-1000mg/天。更优选可以为200-1000mg/天。
番茄红素:番茄红素的量可以为1-150mg/天;优选5-35mg/天。
虾青素:虾青素的量可以为1-150mg/天,优选为2-50mg/天,更优选为5-20mg/天。
β-隐黄质:β-隐黄质的量可以为1-100mg/天;优选2-30mg/天;更优选为5-15mg/天。
β-胡萝卜素:β-胡萝卜素的量可以为1-100mg/天;优选2-20mg/天,更优选5-15mg/天。
玉米黄质:玉米黄质的量可以为1-60mg/天;优选2-20mg/天;更优选3-10mg/天。
叶黄素:叶黄素的量可以为1-100mg/天,优选2-20mg/天,更优选为6-12mg/天。
角黄素:角黄素的量不应超过30mg/天。
代表性每日配方1:
25-OH D3:5-25μg,优选10μg
维生素E:400mg
抗坏血酸:100-1000mg,优选200-1000mg
隐黄质:.10mg
代表性每日配方#2:
25-OH D3:5-25μg,优选12.5μg
维生素E:10mg
抗坏血酸:100-1000mg,优选200-1000mg
叶黄素:6-12mg
(任选的)玉米黄质:6mg
代表性每日配方#3:
25-OH D3:5-25μg,优选12.5μg
维生素E:200-600mg,优选300-500mg
抗坏血酸:100-1000mg,优选200-1000mg
番茄红素:20mg
代表性每日配方#4:
25-OH D3:5-25μg,优选10μg
维生素E:200-600mg,优选300-500mg
抗坏血酸:100-1000mg,优选200-1000mg
虾青素:20mg
代表性每日配方#5:
25-OH D3:5-25μg,优选12.5μg
维生素E:200-600mg,优选300-500mg
抗坏血酸:100-1000mg,优选200-1000mg
β-胡萝卜素:10mg
优选的比值包括以下
任选的附加成分
可以向上面列出的每种营养品、食品补充剂或药品组合物中加入至少一种附加成分。优选加入至少一种,更优选多于一种以下成分。在另一些实施方式中,加入所有以下成分:
维生素D3:维生素D3的量可以为1-100μg/天;优选为1-50μg/天,更优选为5-25μg/天。
维生素B2:维生素B2的量可以为0.5-300mg/天;优选为5-100mg/天,更优选为10-50mg/天。
烟酸:烟酸的量可以为1-300mg/天;优选为5-100mg/天,更优选为10-50mg/天。
泛酸:泛酸的量可以为1-300mg/天;优选为5-100mg/天,更优选为10-50mg/天。
叶酸:叶酸的量可以为50-100μg/天;优选为400-800μg/天,更优选为400-600μg/天。
生物素:生物素的量可以为5μg-10mg/天;优选30μg-5mg/天,更优选0.1-1mg/天。
锌:锌的量可以为1-40mg/天;优选5-40mg/天,更优选10-20mg/天。
铜:铜的量可以为0.4-10mg/天;优选为0.7-5mg/天,更优选为0.9-3mg/天。
锰:锰的量可以为1-10mg/天;优选1-5mg/天,更优选1-3mg/天。
硒:硒的量可以为20-400μg/天;优选为50-200μg/天,更优选为50-100μg/天。
可以制备预混物以提供上述剂量和优选的剂量。形成本发明一部分的一种预混物被配制成使得向1kg营养品、食品补充剂或药品组合物中加入1g预混物,并且得到的营养品、食品补充剂或药品组合物含有任何上文所给出剂量中所述的剂量。当然,各成分的量可以变化,使得向1公吨营养品、食品补充剂或药品组合物中加入1kg预混物,并且得到的饲料含有任何上文所给出剂量中所述的剂量。下文的实施例对此有具体的说明。
制剂
本发明的另一方面涉及营养品组合物,其包含25-OH D、维生素C、维生素E和至少一种根据本发明的类胡萝卜素的组合以及营养学上可接受的载体。
在本文中使用时,术语“营养品”包括:食物制品(food product)、食品(foodstuff)、饮食补充剂、营养补充剂或用于食物制品或食品的补充剂组合物。因此,在另一个实施方式中,本发明涉及营养品,其中所述营养品是食物制品、食品、饮食补充剂、营养补充剂或用于食物制品或食品的补充剂组合物。
在本文中使用时,术语“食物制品”是指适合人消费的任何食物。食物制品可以是经制备和包装的食物(例如蛋黄酱、沙拉酱、面包或乳酪食物)。在本文中使用时,术语“食品”是指适合人消费的任何物质。术语“饮食补充剂”是指以单剂量或多剂量单位包装的用于补充人饮食的少量化合物。饮食补充剂通常不提供大量热量,但可以含有其它微量营养素(例如维生素或矿物质)。术语“营养补充剂”指的是包含饮食补充剂和热量来源的组合的组合物。在一些实施方式中,营养补充剂是膳食替代物或补充剂(例如营养物或能量棒或营养饮料或浓缩物)。
食物制品或食品为例如饮料(如非酒精饮品和酒精饮品)以及要被添加进饮用水和液体食物中的液体制剂,非酒精饮品为例如软饮、运动饮品、果汁(例如橙汁、苹果汁和葡萄汁);柠檬水、茶、类水饮品和乳和其它乳制饮品(例如酸乳饮品)和减肥饮品。在另一实施方式中,食物制品或食品是指包含本发明的组合物的固体或半固体的食物。这些形式可包括但不限于烘焙的商品如蛋糕和曲奇、布丁、乳制品、糕点(confection)、点心食物或冷冻糕点或新产物(novelties)(例如冰激凌、奶昔),制备的冷冻餐食、糖果、点心制品(例如薯片),液体食物如汤、涂抹物、酱、沙拉酱、制备的肉制品、乳酪、酸乳和任何其它含脂肪或油脂的食物,和食物成分(例如小麦粉)。术语“食物制品”或“食品”还包括功能性食物和制备的食物制品,后者是指批准用于人消费的任何预先包装的食物。
本发明的饮食补充剂可以以任何合适的方式被递送。在一些优选的实施方式中,饮食补充剂被配制为用于经口递送。本发明的饮食补充剂的成分包含在可接受的用于经口消耗的赋形剂和/或载体中。载体和由此产生的饮食补充剂自身的实际形式不是关键的。载体可以是液体、凝胶、囊形片(gelcap)、胶囊、粉末、固体片剂(包衣或非包衣的)、茶等等。
饮食补充剂优选地呈片剂或胶囊的形式。合适的赋形剂和/或载体包括麦芽糖糊精、碳酸钙、磷酸二钙、磷酸三钙、微晶纤维素、葡萄糖、米粉、硬脂酸镁、硬脂酸、交联羧甲基纤维素钠、淀粉羟乙酸钠、交聚维酮、蔗糖、植物胶、乳糖、甲基纤维素、聚维酮、羧甲基纤维素、玉米淀粉等等(包括其混合物)。优选的载体包括碳酸钙、硬脂酸镁、麦芽糖糊精及其混合物。使用常规技术将各种成分和赋形剂和/或载体混合并形成期望的形式。本发明的片剂或胶囊可以用肠包衣包裹,所述肠包衣在约6.0到7.0的pH下溶解。在小肠中溶解而不在胃中溶解的合适肠包衣是醋酸邻苯二甲酸纤维素(cellulose acetate phthalate)。配制和施用技术的更多细节可见于最新版的Remington's Pharmaceutical Sciences(MaackPublishing Co.,Easton,PA)。
在另一些实施方式中,饮食补充剂作为适合被消费者添加进食物或饮料中的粉末或液体提供。例如,在一些实施方式中,饮食补充剂可以以粉末的形式被施用给个体,所述粉末例如要通过混合进饮料中使用,或通过搅拌进半固体的食物(如例如布丁、佐食料(topping)、酱、浓汤(puree)、烹调的谷物或沙拉酱)中使用,或通过以其它方式添加进食物(例如封装在食物或饮料容器的盖中,用于就要消耗前释放)使用。饮食补充剂可含有一种或多种惰性成分,特别是如果期望限制由饮食补充剂添加进餐食中的卡路里数时。例如,本发明的饮食补充剂也可以含有任选的成分,包括例如草药、强化剂、着色剂、甜味剂、调味剂、惰性成分等等。
呈现以下非限制性实施例以更好地阐释本发明。
实施例
实施例1
从商业禽群中获得共30只45周龄的肉种母鸡(ROSS 308)用于研究。如表1所示配制基础肉种鸡产卵饮食。计算的营养组成如表2所示。
表1:基础肉种鸡产卵饮食的成分组成
1提供的矿物质预混物(每kg用于处理组1、2和3的饮食):
Cu:18mg;I:1.1mg;Fe:80mg;Mn:150mg;Zn:125mg;Se:0.25mg。
2更多细节请参见表2。
表2.(每千克饮食提供的)维生素预混物组成
表3.计算的基础肉种鸡产卵饮食的营养组成(%)
组成 | %w/w |
粗蛋白 | 16 |
粗脂肪 | 4.2 |
钙 | 3.1 |
钠 | 0.16 |
总磷 | 0.64 |
总ME | 2910kcal/kg |
饮食补充有或未补充69mcg/kg饮食的25-OH D3和抗氧化剂/抗炎剂(维生素E、抗坏血酸、角黄素)以及富化水平的所选维生素。如下所述,根据饲喂方案(受限制和随意),将母鸡随机分配到3个处理组:
基础饮食-受限制饲喂(140g/天)
基础饮食-随意饲喂
基础饮食-随意饲喂+69mcg 25-OH D3/kg饮食+抗氧化剂/抗炎剂。
它们单独饲养在置于受控室中的丝笼中,所述受控室具有14h:10h的光:暗期并处于25±3℃的温度下。水可随意获得。实验期持续10周。饲喂试验后三周,一些禽鸟被用于相关的血浆参数分析。在实验结束时,对母鸡实施安乐死以进行组织样品收集用于进一步研究:
组织形态的尸体剖检
测定脂质和鞘脂谱-血清和组织
测定组织促炎细胞因子
测定胰岛素抵抗
收集胫骨用于骨强度分析
收获心脏(心肌症)和骨骼肌(胸部和大腿)用于肌病分析。
实施例2
结果与讨论
25-OH D3和抗氧化剂/抗炎剂抑制过量饲喂肉母鸡的肥胖和腹部脂肪
种母鸡能够在发育中卵母细胞的卵黄、脂肪组织和肝脏中储存大量多余能量(以甘油三酯的形式)。脂肪生成(即,葡萄糖转化为甘油三酸酯)主要发生在禽鸟的肝脏中,其涉及一系列连接的酶催化反应,包括糖酵解、柠檬酸循环和脂肪酸合成。肝脏的脂肪生成受营养和激素控制,并且高度响应于饮食变化。脂肪组织主要充当具有很少脂肪生成活性的脂质的储存位点。禽鸟的肝脏与脂肪组织的差异脂肪生成能力是关键转录因子:固醇调控元件结合蛋白-1(SREBP-1)的表达的函数。SREBP-1的基因在肝脏中高度表达,但在脂肪组织中的表达程度要低得多。此外,一些脂肪生成酶基因(例如,脂肪酸合酶、苹果酸酶、乙酰辅酶A羧化酶、ATP柠檬酸裂解酶、硬脂酰辅酶A去饱和酶1)的表达直接受SREBP-1的影响。
随意饲喂的种母鸡比受限制饲喂的种母鸡增积更多腹部脂肪。饮食补充25-OHD3和抗氧化剂/抗炎剂改良了随意饲喂对体重和组织重量、特别是相对脂肪组织重量(肥胖症)的有害影响(表4)。25-OH D3和抗氧化剂/抗炎剂提高了随意饲喂母鸡的胫骨强度。
表4. 25-OH D3和抗氧化剂/抗炎剂对随意饲喂肉种母鸡的体重、肝脏重、腹部脂肪重量和胫骨强度的影响
25-OH D3和抗氧化剂/抗炎剂降低了死亡率并改善产卵、卵巢形态和血浆17β雌二醇水平
雌二醇的分泌是成功排卵卵泡的标志。雌二醇除了触发促性腺激素排卵期前急剧上升的作用之外,还是重要的卵巢内生长、分化和存活因子。在处于随意饲料摄取条件下的禽鸟中,包含25-OH D3和抗氧化剂/抗炎剂降低了死亡率以及卵巢退化和卵巢肿瘤样形态的发生率,提高了产卵并维持血浆雌二醇水平。
25-OH D3和抗氧化剂/抗炎剂改良了受损的葡萄糖清除和胰岛素敏感性
在过量饲喂母鸡中,持续10周饮食包含25-OH D3和抗氧化剂/抗炎剂改善胰岛素抵抗,这通过改良空腹血浆葡萄糖和非酯化脂肪酸水平得以证明(表6)。在葡萄糖清除试验中,瘦母鸡在葡萄糖输注后30-60分钟之间显示出非常急剧的清除率,相反,肥胖母鸡在30-90分钟之间具有非常迟缓的清除率(图1)。在胰岛素分泌方面,与瘦母鸡相比,肥胖母鸡在空腹状态和葡萄糖输注后显示出更高的血浆胰岛素水平(图1)。在过量饲喂母鸡中,葡萄糖清除和葡萄糖诱导的胰岛素分泌通过持续3周包含25-OH D3和抗氧化剂/抗炎剂得以矫正(图1)。
表5. 25-OH D3和抗氧化剂/抗炎剂对随意饲喂肉种母鸡的血浆葡萄糖、非酯化脂肪酸(NEFA)和胰岛素的影响
25-OH D3和抗氧化剂/抗炎剂改良了血脂异常
随意饲喂母鸡的血浆甘油三酯、神经酰胺和鞘磷脂水平升高。然而,补充组合的25-OH D3和抗氧化剂/抗炎剂降低了自由饲喂母鸡的血浆中这些脂质代谢物的水平(表6)。
表6. 25-OH D3和抗氧化剂/抗炎剂对随意饲喂肉种母鸡的血浆三酰甘油、神经酰胺和鞘磷脂的影响
25-OH D3和抗氧化剂/抗炎剂减少了组织甘油三酯和神经酰胺含量的积累
与随意饲喂的母鸡相比,饲喂补充的25-OH D3和抗氧化剂/抗炎剂的母鸡的肝脏、心脏和腿部肌肉中甘油三酯和神经酰胺的积累较低(表7)。
表7. 25-OH D3和抗氧化剂/抗炎剂对随意饲喂肉种母鸡的组织三酰甘油和神经酰胺含量的影响
25-OH D3和抗氧化剂/抗炎剂抑制了过量饲喂肉母鸡的组织促炎性IL-1β产生和血浆IL-6浓度
通过饮食补充25-OH D3和抗氧化剂/抗炎剂改良了肥胖相关的炎症,这通过脂肪组织、肝脏、腿肌、胸肌和心脏中的循环IL-6水平和IL-1β产生受抑制得以证明(图2)。
25-OH D3和抗氧化剂/抗炎剂改良了随意饲喂肉种母鸡的脂毒性
肥胖的主要并发症是胰岛素抵抗的发展,胰岛素抵抗是指胰岛素不能在其主要靶组织:骨骼肌和肝脏中引起餐后营养物质储存。不希望受理论束缚,看来两个可能的机制可解释增加的脂肪储备如何影响全身的整体胰岛素敏感性,从而有助于外周组织中胰岛素信号转导的下调。首先,将营养物质递送到细胞或组织超过其储存能力,从而导致产生抑制胰岛素作用的代谢物。特别重要的是,脂质衍生物(例如三酰甘油和神经酰胺)已显示抑制特异性胰岛素信号转导中间体,从而阻断餐后葡萄糖摄取和/或糖原合成。在随意饲喂肉种雌性动物的情况下,这些代谢物在外周组织中持续积累很可能有助于母鸡全身胰岛素抵抗和脂毒性发展的持续状态。其次,增加的肥胖引起慢性炎症状态,其特征在于:由脂肪细胞或由浸润脂肪垫的巨噬细胞产生的促炎细胞因子的循环水平升高。已显示这些炎症介质直接拮抗胰岛素信号转导,而且还诱导分解代谢过程,从而进一步增加营养代谢物向胰岛素响应性器官的递送。
总体而言,导致形成过量饱和脂肪酸并因此在非脂肪组织中积累脂质的过量葡萄糖供应提高了活性脂质(鞘脂)的细胞水平,活性脂质抑制参与代谢调节以及激活的炎症反应和脂毒性发展的信号转导通路。特别地,神经酰胺是将过量营养物(即饱和脂肪酸)和炎性细胞因子连接至诱导胰岛素抵抗的推定中间体。此外,神经酰胺在多种不同的细胞类型中有毒性,并且能够损害心脏、胰腺和脉管系统。此外,25-羟基D3和抗氧化剂/抗炎剂有效改良由于饲喂至饱食的肉种母鸡中出现的肥胖增加而引起的代谢和内分泌失调以及促炎反应的有害作用。
25-OH D3和抗氧化剂/抗炎剂改良了过量饲喂肉母鸡的心脏发病、腹水和炎症
由于脂质积累过多,心脏可变得功能失调。随意饲喂促进甘油三酯在心脏中积累暗示:增加的可用心脏脂肪酸被适应性酯化成甘油三酯。此外,由于随意饲喂,心脏的神经酰胺含量也增加。神经酰胺是脂毒性心肌症中的心脏毒素,其引起炎症反应,这通过免疫细胞的心脏浸润更多得以证明(表9)。
表8. 25-OH D3和抗氧化剂/抗炎剂对随意饲喂肉种母鸡的心脏反应的影响
心脏肥大在临床上代表对心脏工作量增加的适应性反应。然而,心脏对神经和激素因子的反应也可以独立于后负荷或血管阻力的增加而促使肥大变化。肉种母鸡中发生养料过载引起的心脏代偿性增长(表8)。心脏肥大可变得适应不良,最终发展成病理状态,从而导致心脏衰竭。这些结果支持以下事实:心脏中的脂毒性发展和肥大生长倾向于引发炎性反应。
磷酸化STAT-3(信号转导物和转录激活物3)的心脏保护作用近年来越来越清楚。有趣的是,相较于受限制饲喂的种母鸡,组合的25-OH D3和抗氧化剂/抗炎剂在心脏中诱导更高的STAT-3激活(即,STAT-3的磷酸化)(图3),其中在随意饲喂肉种母鸡中观察到了最低的激活。当补充组合的25-羟基D3和抗氧化剂/抗炎剂时,随意饲喂种母鸡的心包内渗出液、心室扩张和腹水的发生率降低。
实施例3
心肌症试验
材料和方法
从商业禽群中获得共30只45周龄的肉种母鸡(ROSS 308)用于研究。如表12所示配制基础肉种鸡产卵饮食。计算的营养组成如表13所示。
表12:基础肉种鸡产卵饮食的成分组成
1提供的矿物质预混物(每kg用于处理组1、2和3的饮食):Cu:18mg;I:1.1mg;Fe:80mg;Mn:150mg;Zn:125mg;Se:0.25mg。
2更多细节请参见下表13。
表13.(每kg饮食提供的)维生素预混物组成
表14.计算的基础肉种鸡产卵饮食的营养组成(%)
饮食补充有或未补充69mcg 25-OH D3/kg饮食的和抗氧化剂(抗坏血酸、角黄素)以及富化水平的所选维生素。如下所述,根据饲喂方案(受限制和随意),将母鸡随机分配到处理组:
1.基础饮食-受限制饲喂(140g/天)
2.基础饮食-受限制饲喂+(69mcg 25-OH D3/kg饮食)+抗氧化剂/抗炎剂
3.基础饮食-随意饲喂
4.基础饮食-随意饲喂+(69mcg 25-OH D3/kg饮食)+抗氧化剂/抗炎剂。
结果:
表15.饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉种母鸡的产卵的影响。
PROD=产卵率(卵/天/母鸡,%);产量=产卵量(卵/母鸡)
结果以平均值±SEM表示。
同一禽群内具有不同上标字母的平均值显著不同(P<0.05)。
图7显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄入的肉母鸡的产卵的影响。从表15和图7可以得出以下结论:
1. 25-OH-D3+抗氧化剂/抗炎剂通过促进存活而提高了总产卵量。
2.在死亡的禽鸟中,25-OH-D3+抗氧化剂/抗炎剂对随意饲喂禽鸟的产卵量和产卵率无影响,但降低了受限制禽鸟的产卵量和产卵率。然而,在整个禽群中,25-OH-D3+抗氧化剂/抗炎剂提高了产卵量,而不是产卵率。
3.这些结果暗示:25-OH-D3+抗氧化剂/抗炎剂加速了对猝死敏感的受限制禽鸟的死亡进程,从而充当禽群选择物(culler)来排除猝死易感禽鸟以获得更长存活,进而降低禽群维护成本。
表16.饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的死亡率的影响和死亡母鸡的身体特征。
结果以平均值±SEM表示。
具有不同上标字母的平均值显著不同(P<0.05)。
图8显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄入的肉母鸡的存活率的影响。
从表16和图8可以得出以下结论:
1. 25-OH-D3+抗氧化剂/抗炎剂提高了禽鸟的存活率。
2.在随意饲喂的禽鸟中,具有25-OH-D3+抗氧化剂/抗炎剂的死亡禽鸟具有较高的体重,但较低的相对肝脏、腹部脂肪和心脏重量,这暗示大部分过量养料可被分配到肌肉,因此,用于增强泵送功能的心脏适应性肥大生长不能满足对较高生长速率(肌肉)的氧气供应的需要,并且可引起心律不齐和心脏衰竭。
表17.饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的35周龄和50周龄的肉母鸡的尸体特征的影响
结果以平均值±SEM表示。
具有不同上标字母的平均值显著不同(P<0.05)。
*;与35周龄时显著不同。
在50周龄的随意饲喂禽鸟中,相对肝脏重量低看起来是由于卵巢退化发展和因此雌激素分泌减少,从而导致用于卵黄沉积的肝脏中脂质合成减少。
图9显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的体重的影响。
表18.饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的死亡母鸡的心脏发病的影响
结果以比值表示。
图10-11说明了:在受限制或随意饲料摄取情况下,饮食补充25-OH-D3+抗氧化剂/抗炎剂物的死亡母鸡的心脏的总体形态。
表17和18以及图9-11的结论和注释:
1.随意饲喂引起心脏适应性肥大,且某些肥大生长可在病理上发展为心室扩张。因此,心脏需要更高的收缩力来维持泵送功能以满足将氧递送到外周组织的血液供应的需要,从而可导致心脏衰竭。
2. 25-OH-D3+抗氧化剂/抗炎剂降低了死亡禽鸟的心脏发病(扩张、心包积液、破裂)发生率。
3.在受限制和随意饲喂的禽鸟中,具有25-OH-D3+抗氧化剂/抗炎剂的禽鸟展示出较少适应性肥大生长。这支持了大部分过量养料可被分配到肌肉的假说,因此,用于增强泵送功能的心脏肥大生长不能满足对较高生长速率(肌肉)的氧气供应的需要,从而可引起心律不齐和心脏衰竭。
表19.饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的心电图(ECG)谱和心律不齐的影响。EGC谱的实例请参见图12和13。
表19以及图12和13的结论和注释:
25-OH-D3+抗氧化剂/抗炎剂降低了随意饲喂肉种母鸡的ECG谱(谱D至G)的不规则发生率和心率不齐并改良了心脏发病诱发的猝死。
图14显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的心肌纤维化的影响(在35周龄时)。条上带有字母的平均值显著不同(P<0.05)。
图14的结论和注释:
1. 25-OH-D3+抗氧化剂/抗炎剂改良了随意饲喂母鸡的心肌纤维化。
图15显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的血浆IL-6(上图)和IL-1β浓度(下图)的影响。结果以平均值±SEM表示(n=6)。条上带有不同字母的平均值显著不同(P<0.05)。
图15的结论和注释:
25-OH-D3+抗氧化剂/抗炎剂改良了随意饲喂母鸡的慢性全身性炎症。
图16显示了饮食补充25-OH-D3+抗氧化剂/抗炎剂对受限制或随意饲料摄取的肉母鸡的心肌细胞凋亡的影响(在35周龄时)。结果以平均值±SEM表示(n=3)。条上带有不同字母的平均值显著不同(P<0.05)。
图16的结论和注释:
1. 25-OH-D3+抗氧化剂/抗炎剂改良了受限制或随意饲料摄取的母鸡的心脏细胞凋亡。
结论:
补充的25-OH D3和抗氧化剂/抗炎剂通过以下方式改良了与过量饲喂肉种雌性动物有关的有害作用:
·降低过量饲喂肉种母鸡的死亡率并改善卵巢功能,从而改善降低繁殖性能
·改善内分泌(胰岛素)信号转导
·减轻脂毒性发展和全身性炎症
·激活针对养料过载诱导的心脏发病机理的心脏保护机制。
Claims (12)
1.适合人使用的组合物、营养品或药品组合物,其包含:25-羟基维生素D(25-OH D)、维生素C、维生素E和一种或更多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素。
2.根据权利要求1所述的组合物、营养品或药品组合物,其还包含至少一种选自以下的生物活性成分:维生素D、维生素B2、维生素B6、烟酸、泛酸、叶酸、生物素、锌、铜、锰和硒。
3.选自以下的组合物、营养品或药品组合物:
配方1:25-OH D:5-25μg;维生素E:200-600mg;抗坏血酸:100-1000mg;和隐黄质:.10mg;
配方2:25-OH D:5-25μg;维生素E:200-600mg;抗坏血酸:100-1000mg;叶黄素:6-12mg;和任选的玉米黄质:6mg;
配方3:25-OH D:5-25μg;维生素E:200-600mg;抗坏血酸:100-1000mg;和番茄红素:20mg;
配方4:25-OH D:5-25μg;维生素E:200-600mg;抗坏血酸:100-1000mg;和虾青素:20mg;
配方#5:25-OH D:5-25μg;维生素E:200-600mg;抗坏血酸:100-1000mg;和β-胡萝卜素:10mg。
4.根据权利要求1-3中任一项的组合物、营养品、药品组合物或预混物,其中所述25-羟基维生素D为25-羟基维生素D3(25-OH D3)。
5.根据权利要求1-4中任一项的组合物、营养品、药品组合物或预混物,其用于治疗、预防人多囊卵巢综合症,延缓人多囊卵巢综合症的发作或改良人多囊卵巢综合症的症状。
6.根据权利要求1-4中任一项的组合物、营养品、药品组合物或预混物,其用于改良食欲过剩者的体重增加。
7.根据权利要求1-4中任一项的组合物、营养品、药品组合物或预混物,其用于赋予选自以下的至少一种心血管益处:
a)清除未酯化脂肪酸;
b)改良血浆血脂异常(甘油三酯、鞘磷脂和神经酰胺);
c)改良肝脏、腿部、胸肌和心脏中的甘油三酯和神经酰胺积累;
d)抑制组织促炎性IL-1β产生和血浆IL-6浓度;
e)通过上调心脏中STAT-3(信号转导物和转录激活物3)的磷酸化来保护心脏并增强心脏功能;
f)抑制免疫细胞浸润到心脏中;
g)降低腹水的发生率;
h)降低心血管问题的发生率;
i)降低心脏发病(扩张、心包积液、破裂)的发生率;
j)降低ECG谱不规则发生率的量;
k)减少心律不齐的发生;
l)改良心肌纤维化;
m)改良慢性全身性炎症;和
n)改良心脏细胞凋亡;和
o)改善胰岛素抵抗和/或血糖调节。
8.根据权利要求1-4中任一项的组合物、营养品、药品组合物或预混物,其用于改善受损的葡萄糖清除和胰岛素敏感性。
9.一种治疗人多囊卵巢综合症、改良多囊卵巢综合症的症状或延缓有发生多囊卵巢综合症的风险的人的所述综合症发作的方法,所述方法包括:向患多囊卵巢综合症或有发生多囊卵巢综合症风险的人施用有效量的组合,所述组合包含:
25-羟基维生素D3、维生素C、维生素E和一种或更多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素。
10.一种赋予心血管益处的方法,所述方法包括:向有此需要的人施用有效量的组合,所述组合包含:
25-羟基维生素D3、维生素C、维生素E和一种或更多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素;
且所述心血管益处是选自以下的至少一种益处:
a)清除未酯化脂肪酸;
b)改良血浆血脂异常(甘油三酯、鞘磷脂和神经酰胺);
c)改良肝脏、腿部、胸肌和心脏中的甘油三酯和神经酰胺积累;
d)抑制组织促炎性IL-1β产生和血浆IL-6浓度;
e)通过上调心脏中STAT-3(信号转导物和转录激活物3)的磷酸化来保护心脏并增强心脏功能;
f)抑制免疫细胞浸润到心脏中;
g)降低腹水的发生率;
h)降低心血管问题的发生率;
i)降低心脏发病(扩张、心包积液、破裂)的发生率;
j)降低ECG谱不规则发生率的量;
k)减少心律不齐的发生;
l)改良心肌纤维化;
m)改良慢性全身性炎症;
n)改良心脏细胞凋亡;和
o)改善胰岛素抵抗和/或血糖调节。
11.一种改良食欲过剩者的体重增加的方法,所述方法包括施用有效量的组合,所述组合包含:
25-羟基维生素D3、维生素C、维生素E和一种或更多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素。
12.一种改善受损的葡萄糖清除和/或胰岛素敏感性的方法,所述方法包括:向有此需要的人施用有效量的组合,所述组合包含:
25-羟基维生素D3、维生素C、维生素E和一种或更多种选自以下的类胡萝卜素:番茄红素、虾青素、隐黄质、β-胡萝卜素、叶黄素、玉米黄质和角黄素。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103769P | 2015-01-15 | 2015-01-15 | |
US62/103,769 | 2015-01-15 | ||
EP15166937 | 2015-05-08 | ||
EP15166937.1 | 2015-05-08 | ||
EP15172721.1 | 2015-06-18 | ||
EP15172721 | 2015-06-18 | ||
PCT/EP2016/050762 WO2016113387A1 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for human nutraceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107105744A true CN107105744A (zh) | 2017-08-29 |
Family
ID=56405272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680005758.1A Pending CN107105744A (zh) | 2015-01-15 | 2016-01-15 | 用于人营养品的25‑羟基维生素d与抗氧化剂/抗炎剂的组合 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10668088B2 (zh) |
EP (1) | EP3244759A1 (zh) |
JP (1) | JP6859570B2 (zh) |
KR (1) | KR20170103823A (zh) |
CN (1) | CN107105744A (zh) |
BR (1) | BR112017015080B1 (zh) |
WO (1) | WO2016113387A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108902985A (zh) * | 2018-06-08 | 2018-11-30 | 唐飞 | 25-羟基维生素d3在制备保健食品中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114982970B (zh) * | 2022-01-29 | 2024-02-09 | 石药集团中诺药业(泰州)有限公司 | 一种辅助保护内腔粘膜的营养素含片及其制备方法 |
WO2023227626A1 (en) * | 2022-05-23 | 2023-11-30 | Dsm Ip Assets B.V. | Method of improving meat pigmentation in an aquatic animal and animal feed composition |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1135469A (ja) * | 1997-07-23 | 1999-02-09 | Teijin Ltd | 慢性心不全の予防治療剤 |
US6034075A (en) * | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
CN1720030A (zh) * | 2002-12-06 | 2006-01-11 | 帝斯曼知识产权资产管理有限公司 | 番茄红素的新用途 |
US20060034912A1 (en) * | 2004-08-12 | 2006-02-16 | Giordano John A | Compositions and methods for nutrition supplementation |
US20100098779A1 (en) * | 2008-10-22 | 2010-04-22 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
US20100112162A1 (en) * | 2002-01-15 | 2010-05-06 | Dsm Ip Assets B.V. | 25-Hydroxy vitamin D3 compositions |
WO2010057811A2 (en) * | 2008-11-19 | 2010-05-27 | Dsm Ip Assets B.V. | Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry |
US20130011377A1 (en) * | 2011-07-07 | 2013-01-10 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
WO2014191153A1 (en) * | 2013-05-31 | 2014-12-04 | Dsm Ip Assets B.V. | Feed supplement and its use |
WO2014202433A1 (en) * | 2013-06-18 | 2014-12-24 | Dsm Ip Assets B.V. | Novel use of canthaxanthin |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793052A (fr) | 1971-12-20 | 1973-06-20 | Upjohn Co | Compositions a base de 25-hydroxycholecalciferol, leur preparation et leur utilisation |
SU1748784A1 (ru) | 1990-12-21 | 1992-07-23 | Московская сельскохозяйственная академия им.К.А.Тимирязева | Способ кормлени цыпл т-бройлеров |
JPH09294544A (ja) | 1996-05-02 | 1997-11-18 | Asao Shimanishi | 養鶏用飼料添加剤 |
US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
BRPI0716775A2 (pt) | 2006-09-14 | 2013-09-24 | Dsm Ip Assets Bv | composiÇço de suplemento alimentar que contem um ou mais compostos de vitamina d3 e um ou mais sais de magnÉsio |
JP2008106023A (ja) | 2006-10-27 | 2008-05-08 | Oriza Yuka Kk | エストラジオール生成促進剤 |
JP5713520B2 (ja) | 2007-07-25 | 2015-05-07 | 日清丸紅飼料株式会社 | ビタミン類を富化した鶏卵およびその鶏卵の生産方法並びにその鶏卵を生産するために用いる飼料 |
BRPI0907950A2 (pt) * | 2008-02-13 | 2015-08-04 | Dsm Ip Assets Bv | Tratamento de hiperglicemia com 25-hidroxivitamina d3 |
KR20100117112A (ko) * | 2008-02-13 | 2010-11-02 | 디에스엠 아이피 어셋츠 비.브이. | 25-하이드록시비타민 d3에 의한 고혈압 치료 |
RU2553650C2 (ru) | 2010-12-23 | 2015-06-20 | Хилл'С Пет Ньютришн, Инк. | Кормовые композиции для домашних животных и способы снижения и поддержания веса |
CN104869842A (zh) | 2012-12-27 | 2015-08-26 | 帝斯曼知识产权资产管理有限公司 | 角黄素和25-羟基维生素d3的新用途 |
US20180000124A1 (en) | 2015-01-15 | 2018-01-04 | Dsm Ip Assets B.V. | Poultry feed with combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories |
-
2016
- 2016-01-15 EP EP16700958.8A patent/EP3244759A1/en active Pending
- 2016-01-15 WO PCT/EP2016/050762 patent/WO2016113387A1/en active Application Filing
- 2016-01-15 JP JP2017530279A patent/JP6859570B2/ja active Active
- 2016-01-15 KR KR1020177019491A patent/KR20170103823A/ko not_active Application Discontinuation
- 2016-01-15 CN CN201680005758.1A patent/CN107105744A/zh active Pending
- 2016-01-15 BR BR112017015080-8A patent/BR112017015080B1/pt active IP Right Grant
- 2016-01-15 US US15/541,793 patent/US10668088B2/en active Active
-
2020
- 2020-04-24 US US15/929,310 patent/US11040045B2/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6034075A (en) * | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
JPH1135469A (ja) * | 1997-07-23 | 1999-02-09 | Teijin Ltd | 慢性心不全の予防治療剤 |
US20100112162A1 (en) * | 2002-01-15 | 2010-05-06 | Dsm Ip Assets B.V. | 25-Hydroxy vitamin D3 compositions |
CN1720030A (zh) * | 2002-12-06 | 2006-01-11 | 帝斯曼知识产权资产管理有限公司 | 番茄红素的新用途 |
US20060034912A1 (en) * | 2004-08-12 | 2006-02-16 | Giordano John A | Compositions and methods for nutrition supplementation |
US20100098779A1 (en) * | 2008-10-22 | 2010-04-22 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
WO2010057811A2 (en) * | 2008-11-19 | 2010-05-27 | Dsm Ip Assets B.V. | Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry |
US20130011377A1 (en) * | 2011-07-07 | 2013-01-10 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
WO2014191153A1 (en) * | 2013-05-31 | 2014-12-04 | Dsm Ip Assets B.V. | Feed supplement and its use |
WO2014202433A1 (en) * | 2013-06-18 | 2014-12-24 | Dsm Ip Assets B.V. | Novel use of canthaxanthin |
Non-Patent Citations (2)
Title |
---|
ANXIASHUO: "帝斯曼最适维生素营养2011英文版", 《《百度文库》:HTTPS://WENKU.BAIDU.COM/VIEW/ 28BCD3F5172DED630B1CB69F.HTML》 * |
闫文杰 等: "维生素D与多囊卵巢综合征相关性的初步研究", 《现代妇产科进展》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108902985A (zh) * | 2018-06-08 | 2018-11-30 | 唐飞 | 25-羟基维生素d3在制备保健食品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
US20190015429A1 (en) | 2019-01-17 |
JP2018503605A (ja) | 2018-02-08 |
WO2016113387A1 (en) | 2016-07-21 |
US20200268773A1 (en) | 2020-08-27 |
JP6859570B2 (ja) | 2021-04-14 |
KR20170103823A (ko) | 2017-09-13 |
EP3244759A1 (en) | 2017-11-22 |
BR112017015080A2 (pt) | 2018-06-19 |
US11040045B2 (en) | 2021-06-22 |
BR112017015080B1 (pt) | 2023-03-07 |
US10668088B2 (en) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tripathi et al. | Estimates for world population and global food availability for global health | |
CA2708258C (en) | Method of producing egg yolk based functional food product and products obtainable thereby | |
RU2557162C2 (ru) | Композиции в виде пюре, имеющие специфические углеводные соотношения и способы их применения | |
CN109645320A (zh) | 一种轻断食全营养配方可冲泡即食棒及其制备方法 | |
US11040045B2 (en) | Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for human nutraceuticals | |
NO333013B1 (no) | Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning. | |
CN107205442A (zh) | 具有25‑羟基维生素d和抗氧化剂/抗炎剂的组合的伴侣动物饲料 | |
JP2016008180A (ja) | 筋肉持久力向上剤 | |
RU2497377C1 (ru) | Корм для кур | |
JP6071988B2 (ja) | 身体活動促進剤 | |
Dike | Importance of designer eggs for the Nigerian population | |
JP7281211B2 (ja) | ジカルボン酸の新たな使用及び適用 | |
Zárate-Chavarría | Intervenciones dietéticas para controlar las dislipidemias y el riesgo cardiovascular | |
WO2018074415A1 (ja) | たんぱく質効率向上用の組成物 | |
NO333305B1 (no) | Sammensetning omfattende bioaktiv aminosyre eller derivater derav og marin olje i en stabil olje-i-vann emulsjon, og fremgangsmate for fremstilling av nevntesammensetning samt forseglet beholder inneholdende sammensetningen | |
Adams | Nutricines: the function in functional foods. | |
Wadhwal et al. | NUTRITIONAL INTERVENTIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |